Poliomyelitis leading to large-scale trials in the then Belgian Congo and the vaccination of seven million children in Poland against serotypes PV1 and PV3 between 1958 and 1960. The second inactivated polio virus vaccine was developed in 1952 by Jonas Salk at the University of Pittsburgh, and announced to the world on 12 April 1955. The Salk vaccine, or inactivated poliovirus vaccine, is based on poliovirus grown in a type of monkey kidney tissue culture (vero cell line), which is chemically inactivated with formalin. After two doses of inactivated poliovirus vaccine (given by injection), 90 percent or more of individuals develop
Jonas Salk it came into use in 1955. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Salk preferred not to have his career as a scientist affected by too much personal attention, as he had always tried to remain independent and private in his research and life, but this proved to be impossible. "Young man, a great tragedy has befallen you—you've lost your anonymity", the television personality Ed Murrow said to Salk shortly after the onslaught of media attention. When Murrow asked him, "Who owns this patent?", Salk